A detailed history of Lindbrook Capital, LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 199 shares of ARDX stock, worth $1,048. This represents 0.0% of its overall portfolio holdings.

Number of Shares
199
Previous 282 29.43%
Holding current value
$1,048
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$5.28 - $7.57 $438 - $628
-83 Reduced 29.43%
199 $1,000
Q2 2024

Jul 31, 2024

BUY
$5.89 - $9.31 $488 - $772
83 Added 41.71%
282 $2,000
Q4 2023

Jan 31, 2024

BUY
$3.29 - $6.64 $654 - $1,321
199 New
199 $1,000
Q2 2021

Jul 27, 2021

SELL
$6.55 - $8.98 $9,825 - $13,470
-1,500 Closed
0 $0
Q1 2021

Apr 28, 2021

BUY
$6.1 - $7.69 $9,150 - $11,535
1,500 New
1,500 $10,000
Q3 2020

Nov 03, 2020

SELL
$5.25 - $7.08 $3,155 - $4,255
-601 Closed
0 $0
Q2 2020

Jul 27, 2020

BUY
$5.37 - $8.11 $3,227 - $4,874
601 New
601 $4,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $815M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.